Harold J Burstein

14PUBLICATIONS
123CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNatural language processingCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Aug 25, 2025
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.

Lorenzo Gerratana, Carolina Reduzzi, Yue Ren

|Nov 05, 2024
Anthracyclines in Early Breast Cancer: The Long Goodbye.

Thomas Grinda, Harold J Burstein

|Aug 27, 2024
Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights.

Igor Makhlin, Lesley Fallowfield, N Lynn Henry

|Jun 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa

|Apr 03, 2024
Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.

Carmine Valenza, Dario Trapani, Sibylle Loibl

|Mar 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.

Erica L Mayer, Yue Ren, Nikhil Wagle

Pageof 3

Frequent Collaborators

6 joint publications

Angela DeMichele

4 joint publications

Kathy Miller

4 joint publications

Eric P Winer

4 joint publications

Meredith M Regan